Cerecin previously Accera Revenue and Competitors
Estimated Revenue & Valuation
- Cerecin previously Accera's estimated annual revenue is currently $6.7M per year.
- Cerecin previously Accera's estimated revenue per employee is $144,891
- Cerecin previously Accera's total funding is $70.1M.
Employee Data
- Cerecin previously Accera has 46 Employees.
- Cerecin previously Accera grew their employee count by -4% last year.
Cerecin previously Accera's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Finance & North American Operations | Reveal Email/Phone |
2 | VP R&D and CMC | Reveal Email/Phone |
3 | VP Corporate Finance | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Director Clinical Quality Assurance | Reveal Email/Phone |
6 | Associate Director Information Technology | Reveal Email/Phone |
7 | Senior Manager, CMC Formulation | Reveal Email/Phone |
8 | Senior Project Manager | Reveal Email/Phone |
9 | CMC Manager, Analytical | Reveal Email/Phone |
10 | Senior Project Manager | Reveal Email/Phone |
Cerecin previously Accera Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A | N/A |
#2 | $2.8M | 18 | 13% | N/A | N/A |
#3 | $70.2M | 453 | -1% | N/A | N/A |
#4 | $1.6M | 10 | -66% | N/A | N/A |
#5 | $3.7M | 24 | -8% | N/A | N/A |
#6 | $2.9M | 37 | 28% | N/A | N/A |
#7 | $3.1M | 20 | 25% | N/A | N/A |
#8 | $2.5M | 16 | -20% | N/A | N/A |
#9 | $9.1M | 59 | 0% | N/A | N/A |
#10 | $4.2M | 27 | -7% | N/A | N/A |
What Is Cerecin previously Accera?
Cerecin, previously Accera, Inc., is a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world. Cerecin is led by an expert executive management team with globally recognized specialists in central nervous system diseases and supported by two partners, Nestle Group and Wilmar Ventures Pte. Ltd. Cerecin's lead compound, tricaprilin, is intended to address the metabolic deficit that is known to be characteristic of Alzheimer's disease by providing the brain with an alternative energy substrate. Cerecin is currently preparing this newly reformulated compound for global pivotal studies. Bringing together the deep industry expertise of its leadership team and the extensive market access capabilities of its strategic investors, Cerecin is growing its global presence to build a brighter future for Alzheimer's patients.
keywords:N/A
$70.1M
Total Funding
46
Number of Employees
$6.7M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cerecin previously Accera News
Cerecin, Inc., a Denver, CO- Melbourne, Australia- and Singapore-based clinical-stage biotechnology company pioneering innovative neurotherapeutics, raised USD $40m in Series A financing. A Series II investment was initially made by long-term investor, Nestlé. In follow up to this round, Series ...
Cerecin, previously Accera, Inc., a Singapore-based brain health-focused pharmaceutical company, raised US$50M in the first close of an investment round. This funding was composed of both equity investment and non-dilutive grants. The round was led by new investor Wilmar Ventures Pte. Ltd., a ...
Other Companies in Denver
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.7M | 46 | -2% | N/A |
#2 | $5.3M | 46 | N/A | N/A |
#3 | $7.3M | 46 | 10% | $118M |
#4 | $7.5M | 46 | -8% | N/A |
#5 | $1.7M | 46 | 10% | N/A |